Eslicarbazepine acetate (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Eslicarbazepine acetate" in English language version.

refsWebsite

Global rank English rank

7nih.gov

4^th place

4doi.org

2^nd place

3europa.eu

68^th place

117^th place

3web.archive.org

1^st place

1tga.gov.au

3,984^th place

2,622^nd place

1hres.ca

low place

1fda.gov

447^th place

338^th place

1zenodo.org

621^st place

380^th place

1semanticscholar.org

11^th place

8^th place

1medicines.org.uk

3,823^rd place

2,387^th place

1prnewswire.co.uk

6,376^th place

4,260^th place

1clinicaltrials.gov

5,225^th place

4,062^nd place

clinicaltrials.gov

Clinical trial number NCT00988156 for "Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in Children" at ClinicalTrials.gov

doi.org

Rogawski MA (June 2006). "Diverse mechanisms of antiepileptic drugs in the development pipeline". Epilepsy Research. 69 (3): 273–94. doi:10.1016/j.eplepsyres.2006.02.004. PMC 1562526. PMID 16621450.
Rogawski MA, Löscher W (July 2004). "The neurobiology of antiepileptic drugs". Nature Reviews. Neuroscience. 5 (7): 553–64. doi:10.1038/nrn1430. PMID 15208697. S2CID 2201038.
Almeida L, Soares-da-Silva P (January 2007). "Eslicarbazepine acetate (BIA 2-093)". Neurotherapeutics. 4 (1): 88–96. doi:10.1016/j.nurt.2006.10.005. PMC 7479690. PMID 17199020.
Grunze H, Kotlik E, Costa R, Nunes T, Falcão A, Almeida L, Soares-da-Silva P (March 2015). "Assessment of the efficacy and safety of eslicarbazepine acetate in acute mania and prevention of recurrence: experience from multicentre, double-blind, randomised phase II clinical studies in patients with bipolar disorder I". Journal of Affective Disorders. 174: 70–82. doi:10.1016/j.jad.2014.11.013. PMID 25484179.

europa.eu

ema.europa.eu

"Zebinix EPAR". European Medicines Agency (EMA). Retrieved 21 January 2021.
"Summary of Product Characteristics for Zebinix" (PDF). European Medicines Agency. p. 14. Archived from the original (PDF) on 2018-09-20. Retrieved 2016-05-22.
"Exalief (eslicarbazepine acetate): Expiry of the marketing authorisation in the European Union" (PDF). European Medicines Agency. 30 July 2012. Archived from the original (PDF) on 20 September 2018. Retrieved 22 May 2016.

fda.gov

"FDA approves Aptiom to treat seizures in adults". US FDA. 8 November 2013. Archived from the original on 11 January 2017. Retrieved 16 December 2019.

hres.ca

hpr-rps.hres.ca

"Summary Basis of Decision (SBD) for Aptiom". Health Canada. 23 October 2014. Retrieved 29 May 2022.

medicines.org.uk

"Zebinix 800mg tablets". Electronic Medicines Compendium (eMC). Retrieved 12 April 2017.

nih.gov

pubmed.ncbi.nlm.nih.gov

Rogawski MA (June 2006). "Diverse mechanisms of antiepileptic drugs in the development pipeline". Epilepsy Research. 69 (3): 273–94. doi:10.1016/j.eplepsyres.2006.02.004. PMC 1562526. PMID 16621450.
Rogawski MA, Löscher W (July 2004). "The neurobiology of antiepileptic drugs". Nature Reviews. Neuroscience. 5 (7): 553–64. doi:10.1038/nrn1430. PMID 15208697. S2CID 2201038.
Almeida L, Soares-da-Silva P (January 2007). "Eslicarbazepine acetate (BIA 2-093)". Neurotherapeutics. 4 (1): 88–96. doi:10.1016/j.nurt.2006.10.005. PMC 7479690. PMID 17199020.
Grunze H, Kotlik E, Costa R, Nunes T, Falcão A, Almeida L, Soares-da-Silva P (March 2015). "Assessment of the efficacy and safety of eslicarbazepine acetate in acute mania and prevention of recurrence: experience from multicentre, double-blind, randomised phase II clinical studies in patients with bipolar disorder I". Journal of Affective Disorders. 174: 70–82. doi:10.1016/j.jad.2014.11.013. PMID 25484179.

ncbi.nlm.nih.gov

Rogawski MA (June 2006). "Diverse mechanisms of antiepileptic drugs in the development pipeline". Epilepsy Research. 69 (3): 273–94. doi:10.1016/j.eplepsyres.2006.02.004. PMC 1562526. PMID 16621450.
Almeida L, Soares-da-Silva P (January 2007). "Eslicarbazepine acetate (BIA 2-093)". Neurotherapeutics. 4 (1): 88–96. doi:10.1016/j.nurt.2006.10.005. PMC 7479690. PMID 17199020.

dailymed.nlm.nih.gov

"Aptiom- eslicarbazepine acetate tablet Aptiom- eslicarbazepine acetate kit". DailyMed. Retrieved 21 January 2021.

prnewswire.co.uk

"Eisai and Bial Announce Partnership Agreement for the European Commercialisation of the Novel Once Daily Anti-Epileptic Zebinix". PR Newswire. 19 February 2009.

semanticscholar.org

api.semanticscholar.org

Rogawski MA, Löscher W (July 2004). "The neurobiology of antiepileptic drugs". Nature Reviews. Neuroscience. 5 (7): 553–64. doi:10.1038/nrn1430. PMID 15208697. S2CID 2201038.

tga.gov.au

"Zebinix". Therapeutic Goods Administration (TGA). 9 June 2021. Retrieved 6 September 2021.

web.archive.org

"FDA approves Aptiom to treat seizures in adults". US FDA. 8 November 2013. Archived from the original on 11 January 2017. Retrieved 16 December 2019.
"Summary of Product Characteristics for Zebinix" (PDF). European Medicines Agency. p. 14. Archived from the original (PDF) on 2018-09-20. Retrieved 2016-05-22.
"Exalief (eslicarbazepine acetate): Expiry of the marketing authorisation in the European Union" (PDF). European Medicines Agency. 30 July 2012. Archived from the original (PDF) on 20 September 2018. Retrieved 22 May 2016.

zenodo.org

Rogawski MA, Löscher W (July 2004). "The neurobiology of antiepileptic drugs". Nature Reviews. Neuroscience. 5 (7): 553–64. doi:10.1038/nrn1430. PMID 15208697. S2CID 2201038.